Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Eligible age
18–70 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.
Sponsor: Massachusetts General Hospital
You may qualify if…
- ✓ 1. Age 18-70 years old.
- ✓ 2. Reaction history consistent with a potential immediate hypersensitivity reaction (pruritus, urticaria, erythema, angioedema, bronchospasm, wheezing, shortness of breath, anaphylaxis, or hypotension) to cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime.
- ✓ 3. English speaking or non-English speaking with translation services available.
You may not qualify if…
- ✕ 1. Severe concomitant medical condition (e.g., unstable coronary artery disease, congestive heart failure, severe chronic obstructive pulmonary disease, poorly controlled asthma, chronic renal failure, cirrhosis, or end-stage liver disease.)
- ✕ 2. History of Clostridioides difficile infection
- ✕ 3. Chronic spontaneous urticaria or systemic mastocytosis
- ✕ 4. Incident reaction required cardiopulmonary resuscitation
- ✕ 5. Reaction to 2 or more cephalosporin antibiotics
- ✕ 6. Active infection or antibiotic treatment within 7 days
- ✕ 7. Treatment with systemic antihistamines or corticosteroids within 7 days
- ✕ 8. Treatment with omalizumab or dupilumab within 60 days
Where it's recruiting
Scottsdale
San Francisco
Boston
Rochester
Nashville
Dallas
Source: ClinicalTrials.gov · NCT06406114 · last updated 2026-11-12